Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma
- PMID: 27638095
- DOI: 10.1016/j.eururo.2016.09.003
Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma
Comment on
-
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.Eur Urol. 2017 Feb;71(2):204-209. doi: 10.1016/j.eururo.2016.05.049. Epub 2016 Jun 16. Eur Urol. 2017. PMID: 27318422
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
